Solid Biosciences (SLDB) EBIAT (2017 - 2024)
Solid Biosciences (SLDB) has disclosed EBIAT for 8 consecutive years, with -$42.6 million as the latest value for Q4 2024.
- Quarterly EBIAT fell 109.64% to -$42.6 million in Q4 2024 from the year-ago period, while the trailing twelve-month figure was -$124.7 million through Dec 2024, down 29.9% year-over-year, with the annual reading at -$174.3 million for FY2025, 39.8% down from the prior year.
- EBIAT hit -$42.6 million in Q4 2024 for Solid Biosciences, down from -$32.7 million in the prior quarter.
- In the past five years, EBIAT ranged from a high of -$15.2 million in Q4 2022 to a low of -$42.6 million in Q4 2024.
- Historically, EBIAT has averaged -$23.4 million across 5 years, with a median of -$21.3 million in 2020.
- Biggest five-year swings in EBIAT: soared 36.69% in 2021 and later plummeted 109.64% in 2024.
- Year by year, EBIAT stood at -$21.4 million in 2020, then increased by 12.89% to -$18.6 million in 2021, then increased by 18.59% to -$15.2 million in 2022, then tumbled by 34.12% to -$20.3 million in 2023, then crashed by 109.64% to -$42.6 million in 2024.
- Business Quant data shows EBIAT for SLDB at -$42.6 million in Q4 2024, -$32.7 million in Q3 2024, and -$25.1 million in Q2 2024.